Focus on...

Brain Cancer

Therapeutic vaccine for brain cancer being studied

January 24, 2012

A vaccine for people newly diagnosed with glioblastoma multiforme—the most aggressive and highest-grade malignant glioma—is being tested at 20 sites nationwide in a phase II trial.
 

Bevacizumab delays return of ovarian cancer

Delicia Honen Yard January 13, 2012

The use of bevacizumab (Avastin) improved progression-free survival in women with ovarian cancer, particularly those at high risk for disease progression.
 

Breast Cancer

In HER2 breast cancer, lapatinib works better with trastuzumab than without

February 01, 2012

Lapatinib is not as effective as trastuzumab against (HER2)-positive breast cancer, but combining the two nearly doubles the effectiveness seen with either one alone.
 

Education Reduces Distress During Breast Cancer Treatment

January 31, 2012

Physical, emotional, and social adjustment occurs over time with or without interventions
 

Cervical Cancer

Should informed consent mean the patient understands?

January 30, 2012

The patient understood that surgery was the best next step in her treatment. Or, did she?
 

Not Enough Americans Being Screened for Cancer

January 26, 2012

Rates of cancer screening in the United States are short of Healthy People 2020 targets for breast, cervical, and colorectal cancer screening
 

Colorectal Cancer

Experimental agent slows progression of colorectal cancer

February 02, 2012

The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.
 

Not Enough Americans Being Screened for Cancer

January 26, 2012

Rates of cancer screening in the United States are short of Healthy People 2020 targets for breast, cervical, and colorectal cancer screening
 

Gastrointestinal Cancer

Experimental agent slows progression of colorectal cancer

February 02, 2012

The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.
 

ASCO Gastrointestinal Cancers Symposium, Jan. 19-21, 2012

January 25, 2012

The American Society of Clinical Oncology's ninth annual Gastrointestinal Cancers Symposium was held from Jan. 19 to 21 in San Francisco; several highlights are detailed.
 

Genitourinary Cancer

Inherited high-risk mutation for prostate cancer identified

January 26, 2012

Researchers have discovered a rare but recurrent mutation that increases the risk of hereditary prostate cancer by up to 20 times.
 

Music-playing headphones keep men calm during prostate biopsy

January 25, 2012

Providing men with noise-canceling headphones that play music may be a simple intervention for reducing their anxiety and pain perception while they are undergoing a prostate biopsy.
 

Glioblastoma

Therapeutic vaccine for brain cancer being studied

January 24, 2012

A vaccine for people newly diagnosed with glioblastoma multiforme—the most aggressive and highest-grade malignant glioma—is being tested at 20 sites nationwide in a phase II trial.
 

Enzyme inhibition may brighten glioma treatment outlook

Delicia Honen Yard July 22, 2011

Medications were able to block a newly identified cancer-promoting pathway and delay glioma growth in mice, suggesting a new treatment option to combat malignant glioma.
 

Gynecologic Cancer

Indices for early symptoms of ovarian cancer may need tweaking

January 27, 2012

The clinical utility of a symptom index for ovarian cancer depends on precisely how it is used and how index-positive women are managed, indicate the results of a recent study.
 

Bevacizumab delays return of ovarian cancer

Delicia Honen Yard January 13, 2012

The use of bevacizumab (Avastin) improved progression-free survival in women with ovarian cancer, particularly those at high risk for disease progression.
 

Head and Neck Cancer

Using ESAs in patients with cancer-related anemia

Sarah Wenger, PharmD; Lisa A. Thompson, PharmD, BCOP January 13, 2012

Although the risks of erythropoietin-stimulating agents can outweigh the benefits, select patients may benefit from these drugs.
 

New approach improves skull-base tumor surgery

December 16, 2011

A new transvestibular endoscopic method for removing tumors at the base of skull features shorter operation and recovery periods, fewer complications, and no scars.
 

Kidney Cancer

Drug Approved for Advanced Kidney Cancer

January 27, 2012

Inlyta has been approved by the FDA to treat advanced renal cell carcinoma in patients who haven't responded to another drug.
 

Bevacizumab delays return of ovarian cancer

Delicia Honen Yard January 13, 2012

The use of bevacizumab (Avastin) improved progression-free survival in women with ovarian cancer, particularly those at high risk for disease progression.
 

Leukemia

Asparaginase Erwinia chrysanthemi (Erwinaze)

January 26, 2012

Asparaginase Erwinia chrysanthemi is a component of a multiagent regimen for the treatment of acute lymphoblastic leukemia in patients with a hypersensitivity to Escherichia coli-derived asparaginase.
 

Cutaneous melanoma begets cutaneous melanoma

Delicia Honen Yard January 06, 2012

Continued skin surveillance is important for survivors of cutaneous melanoma (CM), indicate findings showing that this is the most common second primary cancer among persons with a first CM.
 

Liver Cancer

Mutations in IDH1/2 Seen in Intrahepatic Bile Duct Cancers

January 26, 2012

Mutations found in about a quarter of cholangiocarcinomas of intrahepatic origin.
 

ACS annual report says cancer mortality is decreasing

Delicia Honen Yard January 10, 2012

Cancer incidence rates in men declined by 0.6% per year and remained stable in women and cancer mortality fell by 1.8% per year for men and by 1.6% per year for women between 2004 and 2008.
 

Lung Cancer

New PCR-Based Assay Better Predicts Lung Cancer Survival

January 27, 2012

Assay identifies which early-stage NSCLC patients are at high risk of death after surgical resection
 

Bevacizumab delays return of ovarian cancer

Delicia Honen Yard January 13, 2012

The use of bevacizumab (Avastin) improved progression-free survival in women with ovarian cancer, particularly those at high risk for disease progression.
 

Lymphoma

Coping With Peripheral T-Cell Lymphoma

January 16, 2012

Peripheral T-cell lymphoma (PTCL) is a rare and aggressive form of cancer. This fact sheet explains the condition to newly diagnosed patients and provides sources of support.
 

Using ESAs in patients with cancer-related anemia

Sarah Wenger, PharmD; Lisa A. Thompson, PharmD, BCOP January 13, 2012

Although the risks of erythropoietin-stimulating agents can outweigh the benefits, select patients may benefit from these drugs.
 

Melanoma

ACS annual report says cancer mortality is decreasing

Delicia Honen Yard January 10, 2012

Cancer incidence rates in men declined by 0.6% per year and remained stable in women and cancer mortality fell by 1.8% per year for men and by 1.6% per year for women between 2004 and 2008.
 

Cutaneous melanoma begets cutaneous melanoma

Delicia Honen Yard January 06, 2012

Continued skin surveillance is important for survivors of cutaneous melanoma (CM), indicate findings showing that this is the most common second primary cancer among persons with a first CM.
 

Multiple Myeloma

Multiple Myeloma: Making the Most of Your Medical Appointments

December 19, 2011

Many people see their cancer care as a collaboration. This fact sheet provides tips for patients with multiple myeloma for improving communication with providers during office visits.
 

Cell protein raises blood levels of multiple myeloma drug

Delicia Honen Yard August 25, 2011

The anti-inflammatory agent lenalidomide interacts with a molecule that pumps potentially toxic chemicals out of cells, raising blood levels of the drug and increasing side effects.
 

Ovarian Cancer

BRCA Carriers Have Improved Survival in Ovarian Cancer

January 25, 2012

For patients with invasive epithelial ovarian cancer (EOC), BRCA1 and BRCA2 mutations are associated with improved five-year survival, according to a study.
 

Bevacizumab delays return of ovarian cancer

Delicia Honen Yard January 13, 2012

The use of bevacizumab (Avastin) improved progression-free survival in women with ovarian cancer, particularly those at high risk for disease progression.
 

Pancreatic Cancer

Genetic culprit in pancreatic cancer risk identified

Delicia Honen Yard January 17, 2012

Mutations in the ATM gene may raise a person's hereditary risk for pancreatic cancer, information that could lead to better screening methods for the disease.
 

ACS annual report says cancer mortality is decreasing

Delicia Honen Yard January 10, 2012

Cancer incidence rates in men declined by 0.6% per year and remained stable in women and cancer mortality fell by 1.8% per year for men and by 1.6% per year for women between 2004 and 2008.
 

Prostate Cancer

Inherited high-risk mutation for prostate cancer identified

January 26, 2012

Researchers have discovered a rare but recurrent mutation that increases the risk of hereditary prostate cancer by up to 20 times.
 

Imaging May Spare Nerves in Prostate Cancer Surgery

January 25, 2012

Preoperative MRI led to a change in surgical plan in 27 percent of robot-assisted prostatectomies.
 

Sarcoma

Cutaneous melanoma begets cutaneous melanoma

Delicia Honen Yard January 06, 2012

Continued skin surveillance is important for survivors of cutaneous melanoma (CM), indicate findings showing that this is the most common second primary cancer among persons with a first CM.
 

Cancer risk doubles for organ-transplant recipients

Delicia Honen Yard November 21, 2011

Compared with the general population, recipients of a kidney, liver, heart, or lung transplant have twice as great a risk for diverse infection-related and unrelated cancers.
 

Skin Cancer

Erivedge Approved to Treat Basal Cell Carinoma

January 31, 2012

Erivedge (vismodegib) has been approved by the U.S. Food and Drug Administration to treat the most common form of skin cancer, basal cell carcinoma, the agency said Monday.
 

ACS annual report says cancer mortality is decreasing

Delicia Honen Yard January 10, 2012

Cancer incidence rates in men declined by 0.6% per year and remained stable in women and cancer mortality fell by 1.8% per year for men and by 1.6% per year for women between 2004 and 2008.
 

Web Exclusives

Psychosocial approach useful in managing cancer pain

February 03, 2012

Psychosocial interventions, including skills instruction and education, can help reduce pain in persons with cancer, confirm the results of a recent meta-analysis.
 

Experimental agent slows progression of colorectal cancer

February 02, 2012

The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.
 

In HER2 breast cancer, lapatinib works better with trastuzumab than without

February 01, 2012

Lapatinib is not as effective as trastuzumab against (HER2)-positive breast cancer, but combining the two nearly doubles the effectiveness seen with either one alone.
 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions